Inhibikase Therapeutics (IKT) Other financing activities (2020 - 2025)
Inhibikase Therapeutics (IKT) posted quarterly Other financing activities of $562915.0 for Q4 2025, up 124.33% quarter-over-quarter from $250932.0 in Q3 2025.
Inhibikase Therapeutics (IKT) Other financing activities (2020 - 2025) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Other financing activities for 4 consecutive years, with $562915.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other financing activities changed N/A year-over-year to $562915.0; the TTM figure through Dec 2025 stood at $813847.0 (changed N/A YoY), while the FY2025 annual figure was $845468.0, changed N/A from the prior year.
- Other financing activities climbed to $562915.0 in Q4 2025 per IKT's latest filing, from $250932.0 in the prior quarter.
- Across five years, Other financing activities topped out at $41.1 million in Q4 2021 and bottomed at $34357.0 in Q2 2021.
- Historically, Other financing activities has averaged $7.0 million across 3 years, with a median of $147537.5 in 2021.
- On a YoY basis, Other financing activities climbed as much as 177.66% in 2021 and fell as far as 177.66% in 2021.
- Inhibikase Therapeutics' Other financing activities stood at $41.1 million in 2021, then tumbled by 99.89% to $44142.0 in 2022, then surged by 1175.24% to $562915.0 in 2025.
- Business Quant data shows IKT's Other financing activities at $562915.0 in Q4 2025, $250932.0 in Q3 2025, and $44142.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 562,915.00 |
| Dec 31, 2025 | 562,915.00 |
| Sep 30, 2025 | 250,932.00 |
| Sep 30, 2025 | 250,932.00 |
| Mar 31, 2022 | 44,142.00 |
| Mar 31, 2022 | 44,142.00 |
| Dec 31, 2021 | 41.06 Mn |
| Dec 31, 2021 | 41.06 Mn |
| Sep 30, 2021 | 44,143.00 |
| Sep 30, 2021 | 44,143.00 |
| Jun 30, 2021 | 34,357.00 |
| Jun 30, 2021 | 34,357.00 |
| Dec 31, 2020 | 14.79 Mn |
| Dec 31, 2020 | 14.79 Mn |